Sun Pharma's Organon acquisition positions itself for investor success where rivals stumbled. The deal values Organon at 5-6x Ebitda, significantly cheaper than Lupin's Gavis acquisition and Biocon's Viatris deal. This lower valuation makes the merger immediately accretive to earnings per share from day one. Unlike Lupin, which saw its stock take eight years to recover after acquiring Gavis for $880 million, and Biocon, which faced a year-long decline following its $3 billion Viatris biosimilars purchase, Sun Pharma's strong cash position enables better debt management. The all-cash deal at $14 per share represents a 24% premium to Organon's closing price. Market confidence is evident as Sun Pharma stock surged 6.83% on acquisition announcement, becoming the top Nifty 50 gainer.
Post from MarketNews_en
Log in to interact with content.